SpyGlass Pharma presents BIM-IOL trial data showing 86% of patients off eye drops at 48 months

• SpyGlass Pharma has Phase 3 pivotal trials underway for its BIM-IOL System, targeting three years of bimatoprost therapy for glaucoma or ocular hypertension.
• Phase 1/2 results showed 98% of patients off topical pressure-lowering therapy at 12 months, with a 34% mean intraocular pressure reduction.
• First-in-human results showed 86% off topical therapy at 48 months, with a 37% mean intraocular pressure reduction across all doses.
• No product-related adverse events were recorded through 48 months in the first-in-human trial.
• Cash, cash equivalents and short-term investments totaled $215.8 million as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.